HRP20171912T1 - Dvodjelna funkcionalna komplementacija inducirana dvojnim antigenom - Google Patents

Dvodjelna funkcionalna komplementacija inducirana dvojnim antigenom Download PDF

Info

Publication number
HRP20171912T1
HRP20171912T1 HRP20171912TT HRP20171912T HRP20171912T1 HR P20171912 T1 HRP20171912 T1 HR P20171912T1 HR P20171912T T HRP20171912T T HR P20171912TT HR P20171912 T HRP20171912 T HR P20171912T HR P20171912 T1 HRP20171912 T1 HR P20171912T1
Authority
HR
Croatia
Prior art keywords
domain
antigen
antibody
antigens
fragment
Prior art date
Application number
HRP20171912TT
Other languages
English (en)
Croatian (hr)
Inventor
Gernot Stuhler
Original Assignee
Julius-Maximilians-Universität Würzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171912(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Julius-Maximilians-Universität Würzburg filed Critical Julius-Maximilians-Universität Würzburg
Publication of HRP20171912T1 publication Critical patent/HRP20171912T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
HRP20171912TT 2012-01-13 2013-01-14 Dvodjelna funkcionalna komplementacija inducirana dvojnim antigenom HRP20171912T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12151125 2012-01-13
PCT/EP2013/050603 WO2013104804A2 (en) 2012-01-13 2013-01-14 Dual antigen-induced bipartite functional complementation
EP13704369.1A EP2802607B1 (en) 2012-01-13 2013-01-14 Dual antigen-induced bipartite functional complementation

Publications (1)

Publication Number Publication Date
HRP20171912T1 true HRP20171912T1 (hr) 2018-02-09

Family

ID=47715984

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171912TT HRP20171912T1 (hr) 2012-01-13 2013-01-14 Dvodjelna funkcionalna komplementacija inducirana dvojnim antigenom

Country Status (24)

Country Link
US (3) US20150079093A1 (https=)
EP (3) EP2802607B1 (https=)
JP (1) JP6408915B2 (https=)
KR (2) KR20200040893A (https=)
CN (2) CN108034006A (https=)
AU (1) AU2013208895B2 (https=)
CA (1) CA2861003C (https=)
CY (1) CY1119928T1 (https=)
DK (1) DK2802607T3 (https=)
EA (1) EA033947B1 (https=)
ES (1) ES2653287T3 (https=)
HR (1) HRP20171912T1 (https=)
HU (1) HUE035207T2 (https=)
IL (1) IL233566B (https=)
LT (1) LT2802607T (https=)
MX (1) MX359411B (https=)
NO (1) NO2802607T3 (https=)
PL (1) PL2802607T3 (https=)
PT (1) PT2802607T (https=)
RS (1) RS56773B1 (https=)
SG (1) SG11201403997SA (https=)
SI (1) SI2802607T1 (https=)
WO (1) WO2013104804A2 (https=)
ZA (1) ZA201405658B (https=)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2699596A4 (en) 2011-04-22 2015-01-14 Emergent Product Dev Seattle PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
JP6384930B2 (ja) * 2014-03-25 2018-09-05 ファイブスリー ジェノミックス， エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ がん遺伝子変異の機能確認におけるｒｎａ解析のためのシステムおよび方法
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
CA2970924A1 (en) * 2014-10-31 2016-05-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tetravalent tlr9 bispecific antibody
CN104592391B (zh) * 2015-01-21 2020-08-21 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
US20180072990A1 (en) * 2015-03-20 2018-03-15 Children's National Medical Center Generating virus or other antigen-specific t cells from a naïve t cell population
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
DK3310814T5 (da) 2015-06-16 2024-10-07 Hoffmann La Roche Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse
EP3112375A1 (en) * 2015-07-03 2017-01-04 Ludwig-Maximilians-Universität München Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
EP3362929B1 (en) 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
CN106810610A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US10634680B2 (en) 2016-04-26 2020-04-28 University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
CN105920618A (zh) * 2016-06-13 2016-09-07 上海交通大学医学院附属新华医院 一种生物靶向纳米基因材料及其制造方法
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
EP3714944A1 (en) * 2019-03-29 2020-09-30 Medizinische Hochschule Hannover Car for use in the treatment of hvg disease
CN108085333B (zh) * 2016-11-14 2021-06-29 中国科学院分子植物科学卓越创新中心 一种延缓薯类植物生理性变质的方法
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018136725A1 (en) * 2017-01-19 2018-07-26 Harpoon Therapeutics, Inc. Innate immune cell inducible binding proteins and methods of use
TW201834688A (zh) 2017-02-24 2018-10-01 日商中外製藥股份有限公司 藥學組成物、抗原結合分子、治療方法以及篩選方法
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US11827705B2 (en) * 2017-03-28 2023-11-28 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
GB201719646D0 (en) * 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
US20210070846A1 (en) * 2017-12-21 2021-03-11 Gernot Stuhler Specific dosage regimen for hemibody therapy
EP3788079A4 (en) 2018-05-03 2022-12-21 Shanghai Epimab Biotherapeutics Co., Ltd. ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
CA3100349A1 (en) * 2018-05-17 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
US20210269547A1 (en) * 2018-07-02 2021-09-02 The General Hospital Corporation Antibody tumor-targeting assembly complexes
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
EP3897851A2 (en) * 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
AU2020267131A1 (en) 2019-05-02 2021-11-25 Revitope Limited TEAC and ATTAC immunooncology compositions and methods
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
US20230072955A1 (en) * 2020-01-23 2023-03-09 Exuma Biotech Corp Chimeric antigen receptors to her2 and methods of use thereof
IL294368A (en) * 2020-01-29 2022-08-01 Merus Nv Means and method for modulating mixed effects in immune cells
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
CR20230076A (es) * 2020-07-10 2023-03-13 Hoffmann La Roche Anticuerpos que se unen a células cancerosas y dirigen radionucleótidos a dichas células
US20230357398A1 (en) 2020-09-24 2023-11-09 Morphosys Ag Novel human antibodies binding to human cd3 epsilon
KR20230122618A (ko) 2020-12-21 2023-08-22 알로젠 테라퓨틱스 인코포레이티드 프로테아제 활성화 cd45-게이트 car
JP2024504931A (ja) * 2021-01-12 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体
CN112724236B (zh) * 2021-01-15 2022-03-04 武汉大学 一种两性蛋白1的抗原肽及其抗体与应用
EP4337330A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
AU2022281108A1 (en) * 2021-05-28 2023-12-14 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
CN113846115B (zh) * 2021-09-24 2023-10-17 广州医科大学 一种屋尘螨I类变应原pro-Der p 1重组蛋白及其制备方法与应用
JP2025510189A (ja) 2022-03-24 2025-04-14 アクティニウム ファーマシューティカルズ インコーポレイテッド ヒト化抗ｃｄ４５抗体
CN114773452A (zh) * 2022-04-21 2022-07-22 谭宏凯 牛乳乳清主要过敏原α-乳白蛋白的IgE结合表位
US20230382960A1 (en) * 2022-05-27 2023-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Truncated chlorotoxin fusion proteins and methods of use thereof
AU2023314618A1 (en) * 2022-07-25 2025-03-13 Research Institute At Nationwide Children's Hospital Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis
CN117305248A (zh) * 2022-09-09 2023-12-29 复星凯特生物科技有限公司 抗EGFR和cMet双特异性嵌合抗原受体及其应用
WO2024104988A1 (en) * 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Recombinant binding proteins with activatable effector domain
EP4619428A1 (en) 2022-11-15 2025-09-24 F. Hoffmann-La Roche AG Antigen binding molecules
EP4378529A1 (en) * 2022-12-03 2024-06-05 Universitätsklinikum Hamburg-Eppendorf Antibody for use in a therapy involving effector cell engagement
EP4688841A1 (en) * 2023-04-03 2026-02-11 F. Hoffmann-La Roche AG All-in-one agonistic antibodies
EP4688840A1 (en) * 2023-04-03 2026-02-11 F. Hoffmann-La Roche AG Agonistic split antibodies
WO2024241205A1 (en) * 2023-05-19 2024-11-28 Seoul National University R&Db Foundation Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025016902A1 (en) * 2023-07-14 2025-01-23 Julius-Maximilians-Universität Würzburg Multivalent single-partite antibodies for dual-antigen restricted immunotherapy
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025237931A1 (en) 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE69309472T2 (de) * 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
EP2289942B1 (en) * 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
WO2004016782A1 (ja) 2002-08-16 2004-02-26 The University Of Tokyo 複数の蛋白質の間の相互作用を測定する方法
AU2003271175A1 (en) * 2002-10-11 2004-05-04 Masahiro Abe Cell death-inducing agent
CA2505515C (en) * 2002-11-07 2013-08-27 Erasmus Universiteit Rotterdam Fret probes and methods for detecting interacting molecules
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
GB0421836D0 (en) * 2004-10-01 2004-11-03 Avidex Ltd T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents
EP1962961B1 (en) * 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
CN102186499B (zh) * 2008-08-20 2015-05-20 Ibc医药公司 用于癌症治疗的对接和锁定(dnl)疫苗
GB0919751D0 (en) * 2009-11-11 2009-12-30 King S College Hospital Nhs Fo Conjugate molecule
HRP20241208T1 (hr) * 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju

Also Published As

Publication number Publication date
RS56773B1 (sr) 2018-04-30
CA2861003A1 (en) 2013-07-18
EA201400811A1 (ru) 2014-12-30
IL233566B (en) 2018-07-31
EP2802607B1 (en) 2017-10-04
AU2013208895B2 (en) 2017-07-06
US20150079093A1 (en) 2015-03-19
JP6408915B2 (ja) 2018-10-17
HUE035207T2 (en) 2018-05-02
CA2861003C (en) 2023-03-28
EP2802607A2 (en) 2014-11-19
NO2802607T3 (https=) 2018-03-03
EP3907241A1 (en) 2021-11-10
DK2802607T3 (en) 2018-01-08
SG11201403997SA (en) 2014-08-28
SI2802607T1 (en) 2018-01-31
MX2014008468A (es) 2015-02-05
CY1119928T1 (el) 2018-12-12
CN108034006A (zh) 2018-05-15
JP2015505319A (ja) 2015-02-19
KR20140130679A (ko) 2014-11-11
CN104159923A (zh) 2014-11-19
CN104159923B (zh) 2018-01-23
ZA201405658B (en) 2016-05-25
LT2802607T (lt) 2018-02-12
US20190284296A1 (en) 2019-09-19
PT2802607T (pt) 2018-01-03
EP3333190A1 (en) 2018-06-13
ES2653287T3 (es) 2018-02-06
MX359411B (es) 2018-09-27
HK1200175A1 (en) 2015-07-31
BR112014017182A2 (pt) 2020-10-27
US20220340681A1 (en) 2022-10-27
AU2013208895A1 (en) 2014-08-28
US11427644B2 (en) 2022-08-30
KR102100817B1 (ko) 2020-04-17
IL233566A0 (en) 2014-08-31
KR20200040893A (ko) 2020-04-20
WO2013104804A2 (en) 2013-07-18
EA033947B1 (ru) 2019-12-12
WO2013104804A3 (en) 2013-11-21
PL2802607T3 (pl) 2018-03-30
US20210188997A9 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
HRP20171912T1 (hr) Dvodjelna funkcionalna komplementacija inducirana dvojnim antigenom
JP2015505319A5 (https=)
Muenst et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
HRP20192190T1 (hr) Fuzijski proteini koji sadrže vežući protein i polipeptid interleukin-15 sa smanjenim afinitetom za il15ra i njihova upotreba u terapiji
EP1185867B1 (en) Method for separating cells using immunorosettes
US20190040357A1 (en) Method For Separating Cells Using Immunorosettes and Magnetic Particles
JP2013517487A (ja) がん幹細胞マーカーおよびその使用
JP2020529838A5 (https=)
King et al. A bispecific γδ T-cell engager targeting EGFR activates a potent Vγ9Vδ2 T cell–mediated immune response against EGFR-expressing tumors
MY160662A (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
Zhang et al. Binding affinities/avidities of antibody–antigen interactions: Quantification and scale‐up implications
AU2016299166B2 (en) Methods for detecting tissue infiltrating NK cells
EP2460874B1 (en) Method of separating target cell in biological sample
ZA202209069B (en) Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof
MX2022016300A (es) Anticuerpo anti-trop2.
WO2020223392A3 (en) Cancer associated antibody compositions and methods of use
Viter et al. Bioanalytical system for detection of cancer cells with photoluminescent ZnO nanorods
Linnebacher Tumor-infiltrating B cells come into vogue
Catera et al. Binding of CLL subset 4 B cell receptor immunoglobulins to viable human memory B lymphocytes requires a distinctive IGKV somatic mutation
BR112020023265A2 (pt) uso para prevenir e tratar doenças relacionadas a células supressoras derivadas de mieloide
Kasimir-Bauer et al. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols
Feitz et al. Intermediate filament proteins as tissue specific markers in normal and malignant urological tissues
JPH05504059A (ja) 造血前駆細胞の分離法
Filbert et al. 693 APX601, a Novel TNFR2 antagonist antibody for cancer immunotherapy
US20140162281A1 (en) Compositions and kits for separating cells and method of separating cells using the same